Aevi Genomic Medicine (Formerly Known As Medgenics)
435 Devon Park Drive
Suite 715
Wayne
Pennsylvania
19087
United States
Tel: 610-254-4201
Website: http://www.aevigenomics.com/
193 articles about Aevi Genomic Medicine (Formerly Known As Medgenics)
-
Aevi Genomic Medicine, Inc. Receives Positive Nasdaq Listing Determination
10/15/2019
Aevi Genomic Medicine, Inc. announced that the Nasdaq Hearings Panel has agreed to the transfer of the Company's shares to the Nasdaq Capital Market effective at the open of business on October 15, 2019 and granted the Company until February 3, 2020 to gain and evidence compliance of the Nasdaq Capital Market continued listing requirements..
-
Aevi Genomic Medicine Enters into License Agreement with AstraZeneca for Anti-IL-18 Antibody
8/7/2019
Aevi Genomic Medicine, Inc. (NASDAQ: GNMX, "Aevi") today announced that it has obtained the right to exercise an exclusive global license for MEDI2338, a Phase 2-ready fully human monoclonal antibody (mAb) that targets interleukin 18 (IL-18).
-
Aevi Genomic Medicine to Present at the 2019 Wedbush PacGrow Healthcare Conference
8/6/2019
Aevi Genomic Medicine, Inc. announced that Michael F. Cola, President and Chief Executive Officer, will present at the 2019 Wedbush PacGrow Healthcare Conference on Tuesday, August 13, 2019 at 1:20 p.m. EDT at the Parker New York Hotel in New York, NY.
-
Aevi Genomic Medicine Enters into Worldwide License Agreement with Astellas to Develop and Commercialize a Novel Second Generation mTORC1/2 Inhibitor
7/15/2019
Aevi Genomic Medicine, Inc. (NASDAQ: GNMX, "Aevi") today announced it has entered into an exclusive license agreement with OSI Pharmaceuticals, LLC,
-
Aevi Genomic Medicine Announces Top-Line Results from Placebo-Controlled ASCEND Trial (Parts A & B) of AEVI-001 in Children with ADHD
1/2/2019
Aevi Genomic Medicine, Inc. today announced that the ASCEND trial did not achieve statistical significance on the primary endpoint of reduction of ADHD-RS in either Part A or Part B after 6 weeks of treatment with AEVI-001.
-
Aevi Genomic Medicine to Host KOL Breakfast to Discuss Diagnosis and Treatment Paradigms in ADHD
11/26/2018
Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that the Aevi Genomic Medicine Management team will host a breakfast with Key Opinion Leader (KOL) Robert Findling, M.D., Leonard and Helen R. Stulman Professor in Child and Adolescent Psychiatry at Johns Hopkins University.
-
Aevi Genomic Medicine Reports Third Quarter 2018 Financial Results and Provides Business Update
11/1/2018
Announced today financial and operational results for the three months ended September 30, 2018 and provided an overview of the Company's recent corporate progress.
-
Aevi Genomic Medicine Announces Completion of Enrollment for Part B of the ASCEND Trial
10/15/2018
Top-line data for Parts A and B of ASCEND expected in January 2019.
-
Aevi Genomic Medicine Announces Capital Raise of $4.9M to Accelerate Part B of the ASCEND Trial
8/21/2018
Initiation of enrollment in Part B of the ASCEND trial
-
Aevi Genomic Medicine Announces Completion of Enrollment in Part A of Phase 2 ASCEND Trial in ADHD
8/14/2018
Aevi Genomic Medicine, Inc. today announced that it has completed enrollment in Part A (n=64) of its Phase 2 ASCEND clinical trial.
-
Aevi Genomic Medicine Reports Second Quarter 2018 Financial Results and Provides Business Update
8/2/2018
Announced today financial and operational results for the three months ended June 30, 2018 and provided an overview of the Company's recent corporate progress.
-
Aevi Genomic Medicine, Inc. Announces Novel Co-crystal Version of AEVI-001
7/19/2018
Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) today announced that it received positive feedback from the United States Food and Drug Administration (FDA) on an improved version of the Company's lead development molecule, AEVI-001, identified as AEVI-004.
-
Aevi Genomic Medicine to Present at the The 2018 JMP Securities Life Sciences Conference
6/13/2018
Aevi Genomic Medicine, Inc. announced that Michael F. Cola, President and Chief Executive Officer, will present at the JMP Securities Life Sciences Conference
-
Aevi Genomic Medicine Provides Update on Sample Size Re-estimation for Phase 2 ASCEND Trial in ADHD
6/12/2018
Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) today announced that it will increase the sample size for Part A of its Phase 2 ASCEND clinical trial, which is enrolling a mGluR mutation positive genetic subset of pediatric and adolescent patients with Attention Deficit Hyperactivity Disorder (ADHD), to confirm response to AEVI-001 in these patients.
-
Aevi Genomic Medicine to Present at the Jefferies 2018 Global Healthcare Conference
5/29/2018
Aevi Genomic Medicine, Inc. announced that Michael F. Cola, President and Chief Executive Officer, will present at the Jefferies 2018 Global Healthcare Conference.
-
Aevi Genomic Medicine Reports First Quarter 2018 Financial Results and Provides Business Update
5/15/2018
Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the "Company") announced today financial and operational results for the three months ended March 31, 2018 and provided an overview of the Company's recent corporate progress.
-
Aevi Genomic Medicine Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
3/13/2018
Announced today financial and operational results for the three and twelve months ended December 31, 2017.
-
Aevi Genomic Medicine Expands Collaboration with Kyowa Hakko Kirin
3/7/2018
Early stage program in an ultra-orphan pediatric indication with potential to expand to additional indications post proof of concept.
-
Aevi Genomic Medicine Announces New Appointment to its Board of Directors
12/5/2017
Aevi Genomic Medicine announced today the appointment of Matthew D. Bayley, MD, MBA to its Board of Directors.
-
Aevi Genomic Medicine Reports Third Quarter 2017 Financial Results
11/2/2017
Aevi Genomic Medicine announced today financial and operational results for the quarter ended September 30, 2017 and provided a corporate update.